Blog

For the past couple of years, Novo Nordisk was embroiled in patent litigation with numerous prospective generics for Ozempic.  In the fall of 2024, Novo Nordisk wrapped up existing claims and settled with numerous generics, including Mylan, Dr. Reddy’s, Apotex, Sun Pharmaceuticals, among others.  The terms of those settlement agreements, however, are confidential, leaving investors uncertain as to the expected entry date for generic Ozempic.  Novo Nordisk has two other semaglutide drugs, over which it is currently litigating different patents with generics.  What is the patent landscape for Novo Nordisk’s Semaglutide products, Ozempic, Wegovy and Rybelsus?